August 17, 2015By Mark Terry, BioSpace.com Breaking News Staff At least one analyst is again speculating that Foster City, Calif.-based Gilead Sciences, Inc. (GILD) may be ready to acquire New Haven, Conn.-based Achillion Pharmaceuticals, Inc. (ACHN). Given the company’s strong financial performance this year, many analysts believe Gilead is in the market for a strategic […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Rival generic-drug makers Mylan NV and Perrigo Co. both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April publicly bid for Perrigo, saying a combination would create a strong competitor in the quickly consolidating pharmaceuticals sector. Perrigo has rejected the price as too […]
DUBLIN, Aug. 14, 2015 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the Company’s opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term […]
Boston Scientific (NYSE:BSX) and Abbott (NYSE:ABT) are making cuts from their workforce, according to a California Warn notice report. Boston Scientific is slated to cut 455 employees as it closes 2 facilities in the Fremont and San Jose areas. The company said it is moving the operations to a manufacturing facility in Costa Rica. Help […]
Novo Nordisk (NVO), the world’s largest maker of insulin for diabetics may expand its manufacturing operations to the United States, Bloomberg Business reported this morning. If a U.S. site is built, the facility will focus on manufacturing semaglutide, a medication for type 2 diabetes, Bloomberg said. During an interview with Lars Soerensen, Novo Nordisk’s […]
Drug developer Avalanche Biotechnologies Inc said it would not start a second mid-stage study of its eye drug, which showed only a modest improvement in vision in the first study. Avalanche’s shares fell 15 percent in extended trading on Thursday after closing at $13.83. The drug developer said it was stepping back from clinical trials […]
Ever since Pfizer Inc. (PFE)’s $119 billion bid for UK-based AstraZeneca PLC (AZN) collapsed in May 2014, analysts have speculated on who Pfizer might buy. For several months now, heating up at the moment, those rumors have been that Pfizer might take a shot at UK-based GlaxoSmithKline (GSK). The speculation over a Pfizer-GSK deal […]
Gilead Sciences (NASDAQ:GILD) shares may have rallied 24% this year, but better-than-expected sales and profit have led to analysts ratcheting up their EPS forecasts for next year and that’s kept a lid on its valuation. Given that Gilead Sciences’ forward P/E is below 10 and its shares are 5% off their June highs, the stock […]
Juno Therapeutics Inc.’s second-quarter loss widened as the biopharmaceutical company logged higher expenses as it ramps up operations following its December initial public offering. Research-and-development expenses surged to $60.2 million in the latest period, compared with $6.5 a year earlier, while acquisitions accounted for $77 million of spending in the latest period. Shares, down […]
AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential. AbbVie, which is developing the drug venetoclax with Switzerland’s Roche […]